1) These medical science reports are conclusive that phytocannabinoid therapy is effective in the treatment of Crohn's disease with naturally derived Dronabinol [USAN]
http://www.deadiversion.usdoj.gov/fed_regs/rules/2010/fr1101.htm
Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis"The results of the present study correlate and expand the findings suggesting CBD as a potent compound that is able to modulate experimental gut inflammation. The exact cellular signalling pathways responsible for the effect of CBD still remain unclear, even though, for the first time, we identified PPAR-γ as a key receptor in its action during gut inflammation. However, in this study we demonstrate that during intestinal inflammation, CBD is able to control the inflammatory scenario and the subsequent intestinal apoptosis through the restoration of the altered glia-immune homeostasis. CBD is therefore regarded as a promising therapeutic agent that modulates the neuro-immune axis, which can be recognised as a new target in the treatment of inflammatory bowel disorders."
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028159
The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. "Conclusions and implications:In this model of colitis, THC and CBD not only reduced inflammation but also lowered the occurrence of functional disturbances. Moreover the combination of CBD and THC could be beneficial therapeutically, via additive or potentiating effects."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931570/
An interesting report utilizing a synthetic form of THC/CBDhttp://content.karger.com/produktedb/produkte.asp?DOI=000339072&typ=pdf
A report from practioners in California, that used various forms of cannabis seemingly primarily smoked that proved to be effective.
http://projectcbd.com/Chrohns.Hergenrather.html
Clinical trials utilizing smoked cannabis is shown to be effecting in
Treatment of Crohn's disease with cannabis: an observational study.
http://www.ncbi.nlm.nih.gov/pubmed/21910367
Study entitled, Cannabinoids and the gastrointestinal tract concluded, "The extent to which the effects on gastrointestinal function of cannabinoid receptor agonists or antagonists/inverse agonists can be exploited therapeutically has yet to be investigated as has the extent to which these drugs can provoke unwanted effects in the gastrointestinal tract when used for other therapeutic purposes."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728337/
In study entitled, Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases concluded in part, "Extracts from Cannabis sativa have been used in traditional medicine to treat inflammation and diarrhea... Available studies suggest that CB1 agonists may be useful in emesis, IBD, colon cancer and functional disorders associated with hypermotility and diarrhea, while CB2 agonists may be future drugs used for the treatment of IBD. Additionally, there are strong arguments supporting the use of CBs for the treament of IBS."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174079/
In study, The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility published June 14, 2012 stated in the final sentence of the abstract, "Hopefully, the ongoing worldwide intense research on CBs will soon provide new, safer CB based medicines."
http://content.karger.com/produktedb/produkte.asp?DOI=000339072&typ=pdf
In study, Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome, published March 2012, stated, "Most of the pharmacogenetic associations are reported with intermediate phenotypes in relatively small trials, and confirmation in large clinical trials using validated clinical end points is still required."
http://www.ncbi.nlm.nih.gov/pubmed/22403795 from study reported here:
http://ajpgi.physiology.org/content/302/10/G1075.abstract?maxtoshow=&hits=25&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=105&sortspec=date&resourcetype=HWCIT
2) The anecdotal report of Shona Banda in her book, "Live Free or Die" confirms these medical science reports that phytocannabinoid therapy in the form of edible extracts are therapeutic for treating Crohn's disease.
http://bookstore.authorhouse.com/Products/SKU-000365848/Live-Free-or-Die.aspxAlso,
a youtube presentation was uploaded on Aug 23, 2010 that now has over 50,000 views.
http://www.youtube.com/watch?v=4cQrT0sDxycAnd, a follow up youtube presentation was uploaded on Jan 8, 2011 that now has over 24,000 views.
http://www.youtube.com/watch?v=x_otUB7pVMA
3) This ministry has direct experience with this therapy and relates our finding in the following. A man suffering from Crohn's disease contacted us seeking cannabis extract referred here through Jay from phoenixtears.
http://www.youtube.com/watch?v=V8fIFo2gvOs
At the first, we sent out a cannabis sativa extract as the former cannabis indica from Jamaica brought forward to cancer patients was not available. The results were reported back by this patient as, 'only a slight improvement," but not the healing we had hoped. During this time, medical science reports were becoming available on the Internet that tetrahydrocannabinol (THC) alone was not fully therapeutic. Also, practitioners, caretakers and patients with "doctors recommendations" utilizing cannabis extracts were reporting from the 'medical marijuana' community that tetrahydrocannabinol (THC) alone was not fully therapeutic. Cannabis sativa generally is grown for the 'euphoric' effect and the Cannabidiol (CBD) is bred out as undesirable. This compound CBD is a secondary compound in relation to the tetrahydrocannabinol (THC) and diminishes or attenuates the 'high'. Hence, the reason for having been bred out for the 'euphoric' market. This compound is more prevelant in the cannabis indica strain and is recommended by Rick Simpson in the youtube presentation 'Run from the Cure' and on the
www.phoenixtears.cawebsite. This practitioner claims to be able to cure most internal cancers and a host of other maladies with the ingestion of an extract of cannabis indica.
http://www.youtube.com/watch?v=V8fIFo2gvOs
From this work, we determined that an additional compound Cannabidiol or CBD's are required and from research determined that 1%-2% CBD's are an absolute mininum of acceptable levels of CBD's. With the availability of Cannabidiol now through
www.dixiex.comcannabis extracts of both indica and sativa strains containing tetrahydrocannabinol (THC) can be adjusted to meet this threshold for therapeutic use. We are also now adding cannabis essential oil and capoiba balsam a proven treatment for internal inflamation from South America. A small dab of this 'goo' ingested at night before bedtime is all that is required for the effective treatment of Crohn's disease and Colitis. The latest medical science, practioner and our real time current field reports all confIrm that positive patient response is demonstratable in numbers conforming to Phase 2 Clinical Trials studies. A slight groginess in the morning is the only side effect and the body quickly develops a tolerance. Further information on this 'new formula' is linked.
http://www.facebook.com/editnote.php?draft¬e_id=492652777422023&id=100000319149810
Crohn’s Disease and Ulcerative Colitis Study
If you are a patient with inflammatory bowel disease, IBD, using cannabis to mitigate the symptoms of Crohn’s disease or ulcerative colitis, you are invited to participate in this study. Any patient who describes him/herself as having IBD can fill out the IBD questionnaire, personalized with a unique code number, (Study number) and your email address.
http://cannabisclinicians.org/2011/crohn%E2%80%99s-disease-and-ulcerative-colitis-study/
Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Almost all recent synthetic cannabis users (99% of 975) reported ever use of natural cannabis. Users report a strong preference for natural over synthetic cannabis. The latter (synthetic THC) has a less desirable effect profile. Further research is required to determine longer term consequences of use and comparative dependence potential.
http://www.ncbi.nlm.nih.gov/pubmed/23291209
Adler , Jonathan N. , Colbert , James A. , . (2013) Medicinal Use of Marijuana — Polling Results.
New England Journal of Medicine 368:22,
http://www.nejm.org/doi/full/10.1056/NEJMclde1305159
What is the endocannabinoid system? A brief introduction to how and why cannabis effects the human body as a supplement.
http://www.youtube.com/watch?v=cN18wNxOrYg
CCFA - Crohn's & Colitis Foundation of America STATEMENT DECEMBER 2011
Experimental evidence suggests that endocannabinoids, molecules found in the body that closely resemble compounds found in the cannabis (marijuana) plant, may play a role in limiting intestinal inflammation. IBD patients have been found to have higher levels of cannabinoid receptors in their colonic tissue. Several small studies have shown that a significant proportion of patients with IBD report smoking marijuana to relieve IBD related symptoms, particularly those patients with a history of abdominal surgery, chronic abdominal pain, and/or law quality of life index. However, the medicinal use of marijuana is limted by potential side effects, the risk of smoking, and the lack of direct scientific evidence of clinical effectiveness for intestinal inflammation.
The CCFA Crohn's & Colitis Foundation of America does not endorse the smoking of marijuana by IBD patients, any current state-based medical marijuana programs, or the legalization of marijuana. The CCFA does support the calls by the various health organizations urging review of marijuana's status as a federal Schedule 1 controlled substance with the goal of facilitating the conduct of clinical research and the potential development of cannabinoid based medications.
CCFA Patient Education Committee dated 12/2011
112th Congress 1st Session Senate Resolution 199 in the Senate of the United States May 25, 2011 Supporting the goals and ideals of "Crohn's and Colitis Awareness Week" states in part, Whereas Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel disease, afflict approximately 1,400,000 people in the Unites States, 30 percent of whom are diagnosed as children;....... and......"commends the dedication of health care professionals and biomedical researchers who care for Crohn's disease and ulcerative colitis patients and work to advance basic, genetic, and clinical research aimed at developing new treatments and a cure for Crohn's disease and ulcerative colitis"
http://www.gpo.gov/fdsys/pkg/BILLS-112sres199is/pdf/BILLS-112sres199is.pdf
